DNASE1L3 and hepatocellular carcinoma: The results demonstrated that serum DNASE1L3 activity was higher in healthy individuals than in patients with HCC (Fig. 1H), implying that DNASE1L3 was a potential serum biomarker for diagnosing HCC.